{
    "clinical_study": {
        "@rank": "107450", 
        "arm_group": [
            {
                "arm_group_label": "Low dose (2.5 g of pinitol)", 
                "arm_group_type": "Experimental", 
                "description": "Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects."
            }, 
            {
                "arm_group_label": "Intermediate dose (4.0 g of pinitol)", 
                "arm_group_type": "Experimental", 
                "description": "Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects."
            }, 
            {
                "arm_group_label": "High dose (6.0 g of pinitol)", 
                "arm_group_type": "Experimental", 
                "description": "Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was to assess the acute effects of increasing doses of pinitol on\n      glucose tolerance and insulin sensitivity and to evaluate the absorption of pinitol after\n      consumption of an oral nutritive pinitol-enriched beverage in healthy subjects."
        }, 
        "brief_title": "Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy", 
            "Insulin Sensitivity"
        ], 
        "condition_browse": {
            "mesh_term": "Insulin Resistance"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The inclusion criteria for all subjects were age range of 18-65 years, body mass\n             index of 20-30 Kg/m2 and clinically normal kidney function, liver function, heart\n             function, protein status and haematological profile.\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria were pregnancy or lactation, alteration of carbohydrate\n             metabolism, fasting glycaemia \u22655.55 mmol/l on at least two previous occasions,\n             diabetes, or medication known to interfere with glucose metabolism."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738763", 
            "org_study_id": "WIL-PIN-2011-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Low dose (2.5 g of pinitol)", 
                "Intermediate dose (4.0 g of pinitol)", 
                "High dose (6.0 g of pinitol)"
            ], 
            "description": "Three doses of Fruit Up\u00ae (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.", 
            "intervention_name": "Pinitol", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "3-O-methyl-D-chiro-inositol"
        }, 
        "intervention_browse": {
            "mesh_term": "Inositol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Glucose", 
            "Insulin", 
            "3-O-methyl-D-chiro-inositol"
        ], 
        "lastchanged_date": "November 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "Spain", 
                    "zip": "46017"
                }, 
                "name": "University Hospital Dr Peset"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects: a Randomized Cross-over Placebo-controlled Study", 
        "overall_official": {
            "affiliation": "University of Valencia", 
            "last_name": "Antonio Hern\u00e1ndez Mijares, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Each subject attended the Endocrinology Service in the morning after 12-hour overnight fasting. Blood sample was collected in vacutainer serum separator tubes at baseline (minute 0; while still fasting), 15, 30, 45, 60, 90 and 120 minutes after consumption of the tested product placebo or pinitol-enriched beverage. Glucose concentrations were measured by means of enzymatic assay in an autoanalyzer. Insulin concentrations were determined by enzyme-linked immunosorbent assay.", 
            "measure": "Dose-response curves to assess the change in glucose and insulin concentration after an oral ingestion of different doses of pinitol with respect to the corresponding placebo", 
            "safety_issue": "Yes", 
            "time_frame": "up to 120 minutes"
        }, 
        "reference": [
            {
                "PMID": "19221977", 
                "citation": "Stull AJ, Wood KV, Thyfault JP, Campbell WW. Effects of acute pinitol supplementation on plasma pinitol concentration, whole body glucose tolerance, and activation of the skeletal muscle insulin receptor in older humans. Horm Metab Res. 2009 May;41(5):381-6. Epub 2009 Feb 16."
            }, 
            {
                "PMID": "15514265", 
                "citation": "Campbell WW, Haub MD, Fluckey JD, Ostlund RE Jr, Thyfault JP, Morse-Carrithers H, Hulver MW, Birge ZK. Pinitol supplementation does not affect insulin-mediated glucose metabolism and muscle insulin receptor content and phosphorylation in older humans. J Nutr. 2004 Nov;134(11):2998-3003."
            }, 
            {
                "PMID": "10212830", 
                "citation": "Larner J, Allan G, Kessler C, Reamer P, Gunn R, Huang LC. Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. J Basic Clin Physiol Pharmacol. 1998;9(2-4):127-37."
            }, 
            {
                "PMID": "16822203", 
                "citation": "Kang MJ, Kim JI, Yoon SY, Kim JC, Cha IJ. Pinitol from soybeans reduces postprandial blood glucose in patients with type 2 diabetes mellitus. J Med Food. 2006 Summer;9(2):182-6."
            }, 
            {
                "PMID": "15536472", 
                "citation": "Kim JI, Kim JC, Kang MJ, Lee MS, Kim JJ, Cha IJ. Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. Eur J Clin Nutr. 2005 Mar;59(3):456-8."
            }, 
            {
                "citation": "Kim HJ, Park KS, Lee SK, Min KW, Han KA, Kim YK, Ku BJ. Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus. Ann Nutr Metab. 2012; 60: 1-5."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738763"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Valencia", 
            "investigator_full_name": "Antonio Hern\u00e1ndez Mijares", 
            "investigator_title": "PhD, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Plasma pinitol analysis blood samples were collected into vacutainers containing lithium heparin at baseline, 60, 120, 180 and 240 minutes after consumption of the tested product placebo or pinitol-enriched beverage. Pinitol concentration was determined by gas chromatography/ mass spectrometry", 
            "measure": "Dose-response curves to assess the change in pinitol concentration after an oral ingestion of different doses of pinitol with respect to the corresponding placebo", 
            "safety_issue": "Yes", 
            "time_frame": "up to 240 minutes"
        }, 
        "source": "University of Valencia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Valencia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}